NCT02571725: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 50 planned
- Started
- 23 Feb 2016
- Primary completion
- 2 Dec 2020
- Arms
- Olaparib and Tremelimumab
- Results
- None posted
- 8 Oct 2015: Trial registered
- 23 Feb 2016: Trial started